Haematology 2018

10

Cardiovascular disease after therapy for HL: A detailed analysis of 9 collaborative EORTC-LYSA trials 0 5 10 15 20 25 30 35 40 0 Numberof patients at risk: 2811 947 348 108 9 3 0 0 1775 1246 668 304 150 56 26 14 Time since treatment start (years)

LSQ responder LSQ non-responder Totalcohort

4120 1919 6039

4586

2193

1016

412

159

59

26

14

B

50

Ischemic heart disease Congestive heart failure Pericarditis Valvular disease Arrhythmia Cardiac,other Stroke Peripheral vasculopathy Vascular, other Disease of arterial vessels Venous thrombosis

40

30

20

Cumulative incidence (%)

10

0

0

5

10

15

20

25

30

35

40

Time since treatment start (years)

Numberof patients at risk:

Totalcohort

6039

4586

2193

1045

419

167

63

31

15

Totalcohort

Maraldo et al, Lancet Hemat 2015